指南与共识膀胱癌与上尿路尿路上皮癌

膀胱癌诊断与分期中的多参数MRI与VI-RADS:临床医生指南

Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee.
指南 / 共识 · Eur Urol · 2025-10-31

该指南由美国放射学会VI-RADS指导委员会制定,以叙述性综述形式汇总原始研究、荟萃分析、国际指南及专家共识,阐述mpMRI联合VI-RADS及nacVI-RADS在膀胱癌局部分期与疗效评估中的作用。核心推荐为mpMRI与VI-RADS可提高术前分期准确性、在部分NMIBC中避免重复TURBT,并支持MIBC的MRI路径决策。

要点

  • mpMRI联合VI-RADS可提高膀胱癌术前分期准确性。
  • 在部分NMIBC病例中可帮助避免重复经尿道膀胱肿瘤电切。
  • nacVI-RADS可评估系统治疗后反应并可能指导保膀胱策略。

核心结论

  • mpMRI、VI-RADS与nacVI-RADS是提升风险分层和个体化膀胱癌管理的重要工具。
  • 将其整合入多学科工作流程有可能改善结局并减少过度治疗。

研究设计与样本

  • 制定机构为美国放射学会VI-RADS指导委员会,方法为叙述性文献综述。
  • 综述纳入原始研究、荟萃分析、国际指南与专家共识文件。

主要发现

  • mpMRI联合VI-RADS提高术前分期准确性。
  • 在选定NMIBC病例中有助于避免重复经尿道膀胱肿瘤电切。
  • 在基于MRI的路径中支持MIBC决策。
  • nacVI-RADS可评估系统治疗后治疗反应并可能指导保膀胱方法。

关键数值与推荐

  • 原文未报告具体数值、阈值或推荐等级。

临床怎么用

  • 将mpMRI与VI-RADS用于膀胱癌术前局部分期。
  • 在选定NMIBC中参考VI-RADS以避免重复经尿道膀胱肿瘤电切。
  • 在MIBC的MRI路径中结合VI-RADS支持决策。
  • 使用nacVI-RADS评估系统治疗后反应并辅助保膀胱策略。

局限性

  • 障碍包括可及性差异、指南不一致、判读可重复性问题及有限的成本效果数据。
  • 正在进行的多中心验证与标准化报告有助于缓解上述问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Staging of bladder cancer (BC) remains a cornerstone of treatment planning, especially in distinguishing non-muscle-invasive BC (NMIBC) from muscle-invasive BC (MIBC). Multiparametric magnetic resonance imaging (mpMRI), together with the Vesical Imaging-Reporting and Data System (VI-RADS) and its neoadjuvant chemotherapy version (nacVI-RADS), has emerged as a noninvasive, standardised tool for local staging and response assessment. Our aim was to provide urologists with a practical, up-to-date overview of bladder mpMRI and its application in diverse clinical settings. METHODS: We conducted a narrative review of the literature, including original studies, meta-analyses, international guidelines, and expert consensus documents, on the role of magnetic resonance imaging (MRI) in the BC diagnostic and therapeutic pathway. KEY FINDINGS AND LIMITATIONS: mpMRI with VI-RADS improves the accuracy of preoperative staging, helps in avoiding repeat transurethral resection of bladder tumour in selected NMIBC cases, and supports decision-making in MIBC in MRI-based pathways. nacVI-RADS allows assessment of treatment responses after systemic therapies, and can potentially guide bladder-sparing approaches. Barriers include variability in access, guideline inconsistency, the reproducibility of interpretation, and limited cost-effectiveness data. However, ongoing multicentre validation efforts and standardised reporting are helping to mitigate these issues. CONCLUSIONS AND CLINICAL IMPLICATIONS: mpMRI, VI-RADS, and nacVI-RADS represent essential tools for enhancing risk stratification and personalising BC management in clinical urology practice. Their integration into multidisciplinary workflows has the potential to improve outcomes and reduce overtreatment.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Panebianco V, Briganti A, Efstathiou JA, et al. Multiparametric Magnetic Resonance Imaging and Vesical Imaging-Reporting and Data System (VI-RADS) for Bladder Cancer Diagnosis and Staging: A Guide for Clinicians from the American College of Radiology VI-RADS Steering Committee. Eur Urol. 2025. PMID: 41176432. doi:10.1016/j.eururo.2025.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。